PS
RPRX icon

Principal Securities’s Royalty Pharma RPRX Stock Holding History

Principal Securities’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
35,574
+709
+2% +$36.9K 0.02% 548
2026
Q1 		$1.67M Buy
34,865
+4,635
+15% +$203K 0.02% 560
2025
Q4 		$1.17M Buy
30,230
+4,096
+16% +$156K 0.02% 650
2025
Q3 		$922K Buy
26,134
+25,860
+9,438% +$936K 0.02% 689
2025
Q2 		$9.87K Buy
274
+88
+47% +$2.92K ﹤0.01% 2622
2025
Q1 		$4.75K Hold
186
– – ﹤0.01% 2791
2024
Q4 		$4.75K Buy
186
+139
+296% +$3.69K ﹤0.01% 2788
2024
Q3 		$1.33K Sell
47
-1
-2% -$28 ﹤0.01% 3065
2024
Q2 		$1.27K Buy
48
+39
+433% +$1.08K ﹤0.01% 3016
2024
Q1 		$273 Sell
9
-20
-69% -$590 ﹤0.01% 3212
2023
Q4 		$815 Buy
+29
New +$797 ﹤0.01% 2998

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's RPRX Position: Q2 2026 in Review

Principal Securities increased its Royalty Pharma (RPRX) stake by 2% in Q2 2026, buying an estimated $36.9K and bringing the position to 35,574 shares worth $1.99M. The position accounts for 0.02% of the portfolio, ranked #548.

Principal Securities first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Principal Securities held 35,574 shares of Royalty Pharma worth $1.99M as of Q2 2026.
  • Principal Securities bought 709 Royalty Pharma shares in Q2 2026, an estimated $36.9K.
  • Royalty Pharma made up 0.02% of Principal Securities's portfolio in Q2 2026, its #548 holding.
  • Principal Securities first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.